Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avai Bio (AVAI) Cash & Equivalents (2019 - 2023)

Avai Bio's Cash & Equivalents history spans 4 years, with the latest figure at $896.0 for Q4 2023.

  • For Q4 2023, Cash & Equivalents fell 95.24% year-over-year to $896.0; the TTM value through Dec 2023 reached $896.0, down 95.24%, while the annual FY2023 figure was $107472.0, N/A changed from the prior year.
  • Cash & Equivalents for Q4 2023 was $896.0 at Avai Bio, down from $1480.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $107472.0 in Q1 2023 and bottomed at $102.0 in Q1 2019.
  • The 4-year median for Cash & Equivalents is $8358.0 (2020), against an average of $17367.3.
  • The largest annual shift saw Cash & Equivalents skyrocketed 26665.69% in 2020 before it crashed 97.69% in 2023.
  • A 4-year view of Cash & Equivalents shows it stood at $498.0 in 2019, then soared by 5826.51% to $29514.0 in 2020, then tumbled by 36.26% to $18812.0 in 2022, then crashed by 95.24% to $896.0 in 2023.
  • Per Business Quant, the three most recent readings for AVAI's Cash & Equivalents are $896.0 (Q4 2023), $1480.0 (Q3 2023), and $518.0 (Q2 2023).